This ACTG study is a multicenter, phase II, randomized, double-blind trial which evaluated and compared the efficacy, survival, developmental, and growth parameters; and the development of life-threatening and opportunistic infections following 2 doses of ddI therapy in children with symptomatic HIV infection who have developed toxicity to AZT or who demonstrated disease progression while on AZT.
Showing the most recent 10 out of 638 publications